MedTrace Logo

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

NCT07644312 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-06-12

No results posted yet for this study

Summary

The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.

Conditions

  • High Grade Glioma
  • Diffuse Intrinsic Pontine Glioma
  • WHO Grade 3 Glioma
  • WHO Grade 4 Glioma
  • Replication Repair Deficient

Interventions

DRUG

Opdualag

Fixed dose combination of relatlimab and nivolumab (Opdualag)

Sponsors & Collaborators

  • Nationwide Children's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-03-01
Primary Completion
2033-03-01
Completion
2038-03-01
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07644312 on ClinicalTrials.gov